Actinium gets NYSE American notice for failing $4 million stockholders’ equity listing standard

Actinium Pharmaceuticals, Inc.

Actinium Pharmaceuticals, Inc.

ATNM

0.00
  • Actinium Pharmaceuticals received an NYSE American notice for failing continued listing standards tied to minimum stockholders’ equity.
  • Stockholders’ equity was about $2.3 million as of March 31, 2026, below the $4 million threshold under Section 1003(a)(ii).
  • A compliance plan is due June 26, 2026, targeting a return to compliance by Nov. 27, 2027.
  • Shares continue trading under ATNM; failure to submit an acceptable plan could trigger delisting proceedings.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Actinium Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202605291730PR_NEWS_USPR_____NY71700) on May 29, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.